Improved supply capabilities of Neuraceq ® to provide better patient access to beta-amyloid PET BOSTON , Aug. 20, 2024 /PRNewswire/ -- Life Molecular Imaging (LMI) and PharmaLogic Holdings Corp. (PharmaLogic), a world-class contract development and manufacturing organization (CDMO) and radiopharmacy solutions provider, announce their new strategic partnership and licensing agreement to provide and distribute Neuraceq ® from PharmaLogic's radiopharmaceutical manufacturing site located near Denver, CO.
The first doses were made available on August, 20 th , 2024. Neuraceq ® is an FDA-approved imaging agent for the detection of beta-amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Neuraceq ® is used in clinical routine and is also a powerful imaging biomarker for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs, or for enrollment in clinical trials to further support drug development in neurodegenerative diseases.
"By partnering with PharmaLogic and offering Neuraceq ® in Denver , Life Molecular Imaging is excited to expand access of Neuraceq ® for the detection of beta-amyloid plaques in the brain. We believe this additional access benefits physicians and patients, as well as our pharma partners for routine clinical and research use. We are excited to collaborate with Pharmalogic today and look .